[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sironax USA, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100651847","phase-2-study-of-sir2501-in-solid-tumor-patients-receiving-paclitaxel-100651847",false,"NCT07765446","Study of SIR2501 in Solid Tumor Patients Receiving Paclitaxel","A Phase 2, Open-Label Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SIR2501 and Its Potential to Address Paclitaxel-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Adults ≥18 years with confirmed solid tumors\n* Planned treatment with paclitaxel-based chemotherapy\n* ECOG performance status 0-2\n\nExclusion Criteria:\n\n* Pre-existing peripheral neuropathy\n* Conditions or medications that may interfere with neuropathy assessment\n* Prior exposure to neurotoxic chemotherapy\n* Use of medications known to mitigate CIPN\n* Significant medical conditions that may increase study risk","ALL","18 Years",{"count":19,"type":20},18,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This Phase 2, open-label study will evaluate the safety, tolerability, and pharmacokinetics of SIR2501 in adults with solid tumors who are scheduled to receive paclitaxel-based chemotherapy. The study will also explore whether SIR2501 has the potential to reduce the development of chemotherapy-induced peripheral neuropathy (CIPN).",[26],"Chemotherapy-induced Peripheral Neuropathy",[28,29],"CIPN","Paclitaxel","NOT_YET_RECRUITING","2026-08-10",{"date":33,"type":34},"2026-08-14","ACTUAL",{"date":36,"type":20},"2026-08-03",{"date":38,"type":20},"2027-12-31",{"name":40,"class":41},"Sironax USA, Inc.","INDUSTRY",2,""]